Treatments and devices for future diabetes management.
This last article in this three-part series discusses the evolution of diabetes therapy and examines new treatments and delivery devices that are under development to help meet treatment and management targets.
Capaldi
Brenda
B
Gartnavel Diabetes Centre, Glasgow.
D020909:Acarbose / Q000627:therapeutic use; D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000284:Administration, Oral; D001549:Benzamides / Q000627:therapeutic use; D015190:Blood Glucose Self-Monitoring / Q000639:trends; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000453:epidemiology; D004338:Drug Combinations; D005544:Forecasting; D005934:Glucagon / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D065089:Glycoside Hydrolase Inhibitors; D006285:Health Planning; D006801:Humans; D007004:Hypoglycemic Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000627:therapeutic use; D007332:Insulin Infusion Systems / Q000639:trends; D010446:Peptide Fragments / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011498:Protein Precursors / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D013222:State Medicine; D033581:Stem Cell Transplantation; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use; D006113:United Kingdom / Q000453:epidemiology
C475520:1-(((3-hydroxy-1-adamantyl)amino)acetyl)-2-cyanopyrrolidine; D001549:Benzamides; D004338:Drug Combinations; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D010446:Peptide Fragments; D011498:Protein Precursors; D011759:Pyrrolidines; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D052216:Glucagon-Like Peptide 1; C030516:meglitinide; D005934:Glucagon; D000218:Adamantane; D020909:Acarbose